NASDAQ · VRCA
Verrica Pharmaceuticals Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for VRCA: Nov 13, 2026
Verrica Pharmaceuticals Inc. Common Stock is estimated to report earnings on 11/13/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 1 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.5. The reported EPS for the same quarter last year was $0.05.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.50 | $-0.50 | $-0.50 | 1 |
| Dec 2026 | $-0.41 | $-0.41 | $-0.41 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · The Motley Fool · MarketBeat · Zacks- RTTNews · Aug 19, 11:23 AM EDTVerrica Pharma Gains: What Is The Buzz?(RTTNews) – The shares of Verrica Pharmaceuticals (VRCA), a therapeutics company, were trading up more than 5% with no immediately apparent company-specific catalyst.
- The Motley Fool · Aug 13, 8:59 PM EDTVerrica (VRCA) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- MarketBeat · Aug 7, 3:04 PM EDTVerrica Pharmaceuticals Q2 Earnings Call HighlightsVerrica Pharmaceuticals (NASDAQ:VRCA) reported second-quarter revenue growth in its YCANTH treatment for molluscum contagiosum, while outlining progress in pivotal studies of the product for common warts and announcing a credit facility that management said could extend its cash
- Zacks · Aug 6, 7:10 PM EDTVerrica Pharmaceuticals Inc. (VRCA) Reports Q2 Loss, Beats Revenue EstimatesVerrica Pharmaceuticals (VRCA) delivered earnings and revenue surprises of +14.29% and +1.77%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · Jun 22, 12:45 PM EDTVerrica Doses First U.S. And Japanese Patients In Phase 3 COVE-3 Trial For YCANTH In Common Warts(RTTNews) – Verrica Pharmaceuticals Inc. (VRCA), a therapeutics company, on Monday announced the dosing of the first U.S. patient in the Phase 3 COVE-3 trial for YCANTH in treating common warts. Additionally, Torii Pharmaceutical Co. Ltd., the company's pharmaceutical partner, an
- The Motley Fool · May 13, 10:13 AM EDTVerrica (VRCA) Q1 2026 Earnings Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- MarketBeat · May 12, 11:07 PM EDTVerrica Pharmaceuticals Q1 Earnings Call HighlightsVerrica Pharmaceuticals (NASDAQ:VRCA) reported higher first-quarter revenue and record demand for its molluscum contagiosum treatment YCANTH, while outlining progress on late-stage development programs in common warts and basal cell carcinoma. President and Chief Executive Offic
- Zacks · May 12, 5:15 PM EDTVerrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue EstimatesVerrica Pharmaceuticals (VRCA) delivered earnings and revenue surprises of +30.51% and +6.87%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · May 7, 3:15 PM EDTLipocine (LPCN) Reports Q1 Loss, Beats Revenue EstimatesLipocine (LPCN) delivered earnings and revenue surprises of -5.88% and +19.40%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · May 6, 5:41 AM EDTVerrica To Present Positive Phase 2 Data For VP-315 In Treating Basal Cell Carcinoma At SID Meeting(RTTNews) – Verrica Therapeutics Inc. (VRCA), a dermatology therapeutics company, on Tuesday announced the presentation of Phase 2 data indicating an abscopal effect for VP-315 in treating basal cell carcinoma at the Society for Investigative Dermatology (SID) annual meeting on M
- Zacks · May 5, 5:15 PM EDTNeurocrine Biosciences (NBIX) Beats Q1 Earnings and Revenue EstimatesNeurocrine (NBIX) delivered earnings and revenue surprises of +15.31% and +9.80%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
- RTTNews · Mar 12, 1:39 AM EDTVerrica Pharma Q4 And FY25 Revenue Improves; Plans Second Phase 3 Program For VP-102 In Mid 2026(RTTNews) – Verrica Pharmaceuticals Inc. (VRCA), a commercial-stage dermatology therapeutics company, reported a narrower net loss for the fourth quarter and full year 2025, driven by revenue growth from its lead product, YCANTH(VP-102).
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Verrica Pharmaceuticals Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.